Shots:

• The sBLA submission is based on an ongoing P-II ZUMA-5 study assessing single infusion of Yescarta in ~160 patients (≥18 yrs.) with r/r indolent NHL of either FL or marginal zone lymphoma subtypes- prior treated with 2L therapies- including an anti-CD20 mAb combined with an alkylating agent
• The 1EPs of the study is ORR as assessed by IRC while 2EPs include CRR- DOR- PFS- OS- safety and CAR T cell and cytokines levels
• Yescarta is a CD19-directed genetically modified autologous T cell immunotherapy and has received the US FDA’s BT designation for indolent NHL. If approved- Yescarta would become the first CAR T cell therapy for this indication

­ Ref: Gilead | Image: Glassdoor